Heparin is the primary anticoagulant for cardiopulmonary bypass (CPB) support during cardiac surgery. While widely used, ∼2% of cardiac surgery patients develop heparin-induced thrombocytopenia (HIT) and 4–26% develop heparin resistance. Bivalirudin is an alternative anticoagulant mainly used for percutaneous coronary interventions. Given the challenges associated with heparin anticoagulation, we conducted a review to explore the use of bivalirudin for CPB surgery.
Methods
PubMed and Embase scoping review included 2 randomized controlled trials, a retrospective comparison study, 3 pilot studies, and 30 case reports. To provide a contemporary series, we searched for articles published from 2010 to 2023. Our review included studies from both adult and pediatric populations.
Results
While data is limited, bivalirudin seems to supply similar effectiveness and safety as heparin for CPB anticoagulation. Across the three comparative studies, the heparin cohorts had a 0–9% mortality rate and 0–27% rate of major bleeding/reoperation compared to a 0–3% mortality and 0–6% major bleeding/reoperation rate for the bivalirudin cohorts. Bivalirudin was successfully used as an anticoagulant in a wide range of CPB surgeries (e.g., heart transplants, ventricular assisted device placements, and valve repairs). Successful patient outcomes were reported with bivalirudin infusion of ∼2 mg/kg/hour, activated clotting time monitoring (target >400 s or 2.5× baseline), use of cardiotomy suctions, minimization of stagnant blood, and post-bypass modified ultrafiltration.
Conclusion
Bivalirudin is a safe and effective anticoagulant for CPB, especially for patients with HIT or heparin resistance. Further comparative research is called for to optimize bivalirudin utilization for CPB during cardiac surgery.
ErdoesGOrtmannEMartinez Lopez De ArroyabeB, et al.Role of bivalirudin for anticoagulation in adult perioperative cardiothoracic practice. J Cardiothorac Vasc Anesth2020; 34: 2207–2214.
2.
ChenYPhoonPHYHwangNC. Heparin resistance during cardiopulmonary bypass in adult cardiac surgery. J Cardiothorac Vasc Anesth2022; 36: 4150–4160.
BeurskensDMHHuckriedeJPSchrijverR, et al.The anticoagulant and nonanticoagulant properties of heparin. Thromb Haemost2020; 120: 1371–1383.
5.
CarlsonDSBartholomewJRGomesMP, et al.Outcomes of cardiovascular surgery utilizing heparin versus direct thrombin inhibitors in cardiopulmonary bypass in patients with previously diagnosed HIT. Thromb Haemost2020; 120: 300–305.
6.
SniecinskiRMNielsenVGTanakaK. Searching for an alternate anticoagulant for cardiopulmonary bypass: does two plus two equal two?Anesth Analg2022; 135: 49–51.
7.
SellengSSellengK. Heparin-induced thrombocytopenia in cardiac surgery and critically ill patients. Thromb Haemost2016; 116: 843–851.
8.
BursteinDKimmelSPuttM, et al.Cost-effectiveness of bivalirudin in pediatric ventricular assist devices. J Heart Lung Transplant2023; 42: 390–397.
9.
RevellyEScalaERosnerL, et al.How to solve the conundrum of heparin-induced thrombocytopenia during cardiopulmonary bypass. J Clin Med2023; 12: 786. DOI: 10.3390/jcm12030786.
10.
BryantMEReganWLFynn-ThompsonF, et al.Comparison of two pediatric cases requiring the use of bivalirudin during cardiopulmonary bypass. Perfusion2018; 33: 525–532.
11.
RantaLScalaE. GTH 2021 state of the art-cardiac surgery: the perioperative management of heparin-induced thrombocytopenia in cardiac surgery. Hämostaseologie2021; 41: 59–62.
SolankiJShenoySDownsE, et al.Heparin-induced thrombocytopenia and cardiac surgery. Semin Thorac Cardiovasc Surg2019; 31: 335–344.
14.
SalterBSWeinerMMTrinhMA, et al.Heparin-induced thrombocytopenia: a comprehensive clinical review. J Am Coll Cardiol2016; 67(21): 2519–2532.
15.
AugoustidesJGT. Update in hematology: heparin-induced thrombocytopenia and bivalirudin. J Cardiothorac Vasc Anesth2011; 25: 371–375.
16.
ZapataDBinongoJLasanajakY, et al.Heparin-induced thrombocytopenia in patients undergoing valvular and aortic surgery: a modern assessment of risk. Innovat Tech Tech CardioThorac Vasc Surg2020; 15: 229–234.
17.
Wanat-HawthorneATanakaKAngonaR, et al.Survey of practice pattern in patients with heparin-induced thrombocytopenia requiring cardiopulmonary bypass. Anesth Analg2021; 133: 1180–1186.
18.
HoganMBergerJS. Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med2020; 25: 160–173.
19.
PollakUMishalyDKenetG, et al.Heparin-induced thrombocytopenia complicating children after the Fontan procedure: single-center experience and review of the literature. Congenit Heart Dis2018; 13: 16–25.
20.
RamuBCogswellRJRedingMT, et al.Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients. J Heart Lung Transplant2018; 37(8): 1038–1040.
21.
KosterAErdoesGNaglerM, et al.How would we treat our own heparin-induced thrombocytopenia during cardiac surgery?J Cardiothorac Vasc Anesth2021; 35: 1585–1593.
22.
KosterAFaraoniDLevyJH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology2018; 128: 390–400.
23.
FinleyAGreenbergC. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg2013; 116: 1210–1222.
24.
LevyJHConnorsJM. Heparin resistance — clinical perspectives and management strategies. N Engl J Med2021; 385: 826–832.
25.
ZaleskiKLDiNardoJANasrVG. Bivalirudin for pediatric procedural anticoagulation: a narrative review. Anesth Analg2019; 128: 43–55.
26.
DykeCMSmediraNGKosterA, et al.A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the evolution-on study. J Thorac Cardiovasc Surg2006; 131: 533–539.
27.
BuckML. Bivalirudin as an alternative to heparin for anticoagulation in infants and children. J Pediatr Pharmacol Ther2015; 20(6): 408–417.
28.
ZaleskiKLDiNardoJAEatonMP. Bivalirudin: are kids just adults to the ¾ power?Paediatr Anaesth2021; 31: 628–630.
29.
GarlandCSomogyiD. Successful implantation of a left ventricular assist device in a patient with heparin-induced thrombocytopenia and thrombosis. J Extra Corpor Technol2014; 46(2): 162–165.
30.
ForbesTJHijaziZMYoungG, et al.Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv2011; 77: 671–679.
31.
FaraoniDKosterA. Bivalirudin for anticoagulation during cardiopulmonary bypass in children with congenital heart disease: are we ready yet?J Cardiothorac Vasc Anesth2018; 32: 2641–2643.
32.
GatesRYostPParkerB. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients. Artif Organs2010; 34: 667–669.
33.
AnandSXViles-GonzalezJFMahboobiSK, et al.Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition. Can J Anesth2011; 58: 296–311.
34.
IbrahimWNakiaHStephenM, et al.A patient with remote heparin-induced thrombocytopenia and antiphospholipid syndrome requiring cardiopulmonary bypass: do current guidelines apply?Semin CardioThorac Vasc Anesth2019; 23: 256–260.
35.
EsperSASubramaniamKTanakaKA. Pathophysiology of cardiopulmonary bypass: current strategies for the prevention and treatment of anemia, coagulopathy, and organ dysfunction. Semin CardioThorac Vasc Anesth2014; 18: 161–176.
36.
HassenKMaccaroniMRSabryH, et al.Management of refractory bleeding post-cardiopulmonary bypass in an acute heparin-induced thrombocytopenia type II renal failure patient who underwent urgent cardiac surgery with bivalirudin (Angiox®) anticoagulation. Perfusion2018; 33: 235–240.
37.
McNairEDMarcouxJABallyC, et al.Bivalirudin as an adjunctive anticoagulant to heparin in the treatment of heparin resistance during cardiopulmonary bypass-assisted cardiac surgery. Perfusion2016; 31: 189–199.
38.
SharmaGHasijaSKapoorPM. Perfusion strategies for bivalirudin anticoagulation: AIIMS protocol. J Cardiac Crit Care TSS2022; 6(1): 54–58.
39.
GoswamiDDiGiustoMWadiaR, et al.The use of bivalirudin in pediatric cardiac surgery and in the interventional cardiology suite. J Cardiothorac Vasc Anesth2020; 34: 2215–2223.
40.
Shore-LessersonLBakerRAFerrarisV, et al.STS/SCA/AmSECT clinical practice guidelines: anticoagulation during cardiopulmonary bypass. J Extra Corpor Technol2018; 50(1): 5–18. https://www.americanheart.org/
41.
Shore-LessersonLBakerRAFerrarisVA, et al.The society of thoracic surgeons, the society of cardiovascular anesthesiologists, and the American society of extracorporeal technology: clinical practice guidelines - anticoagulation during cardiopulmonary bypass. Anesth Analg2018; 126: 413–424.
42.
HasijaSTalwarSMakhijaN, et al.Randomized controlled trial of heparin versus bivalirudin anticoagulation in acyanotic children undergoing open heart surgery. J Cardiothorac Vasc Anesth2018; 32: 2633–2640.
43.
KosterABuzSKrabatschT, et al.Bivalirudin anticoagulation during cardiac surgery: a single-center experience in 141 patients. Perfusion2009; 24: 7–11.
44.
HasijaSHoteMPMakhijaN, et al.Bivalirudin anticoagulation in neonates and infants undergoing cardiac surgery. J Cardiothorac Vasc Anesth2022; 36: 3841–3846.
45.
KosterAYeterRBuzS, et al.Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study. J Thorac Cardiovasc Surg2005; 129: 1391–1394.
46.
AddeoPMazzucotelliJPBachellierP. A 2-stage surgical approach for adrenocortical carcinoma with intracardiac extension. Ann Thorac Surg2022; 114: e371–e373.
47.
WilliamsMLTanCMisfeldM, et al.Cytoreductive surgical resection of a rare pulmonary artery intimal sarcoma involving the pulmonary valve and right ventricle: a case report. J Surg Case Rep2021; 2021: rjab051. DOI: 10.1093/jscr/rjab051.
48.
ChoxiAAPatelPAAugoustidesJG, et al.Bivalirudin for cardiopulmonary bypass in the setting of heparin-induced thrombocytopenia and combined heart and kidney transplantation—diagnostic and therapeutic challenges. J Cardiothorac Vasc Anesth2017; 31: 354–364.
49.
NagleELTsuLVDagerWE. Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor vila for iatrogenic coagulopathy. Ann Pharmacother2011; 45(9): e47.
50.
PericleousASadekMFitzmauriceM, et al.Anticoagulation with bivalirudin during deep hypothermic circulatory arrest in a patient with heparin-induced thrombocytopenia. Tex Heart Inst J2014; 41: 645–648.
51.
KosterAAmin-ParsaMKaufmannM, et al.Fulminate heparin-induced thrombocytopenia and surgery with deep hypothermic circulatory arrest using bivalirudin. Ann Thorac Surg2013; 95: 1079–1081.
52.
MujahidOMPrakashMChoudhuryM. ROTEM and bivalirudin: the confounding challenges ahead. Journal of Cardiac Critical Care TSS2023; 7: 71–74.
53.
WolstencroftPArnoldPAndersonBJ. Dose estimation for bivalirudin during pediatric cardiopulmonary bypass. Paediatr Anaesth2021; 31: 637–643.
54.
KamataMSebastianRMcConnellPI, et al.Perioperative care in an adolescent patient with heparin-induced thrombocytopenia for placement of a cardiac assist device and heart transplantation: case report and literature review. Int Med Case Rep J2017; 10: 55–63.
55.
AlmondCSDHarringtonJThiagarajanR, et al.Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. J Heart Lung Transplant2006; 25: 1376–1379.
56.
FaellaKHWhitingDFynn-ThompsonF, et al.Bivalirudin anticoagulation for a pediatric patient with heparin-induced thrombocytopenia and thrombosis requiring cardiopulmonary bypass for ventricular assist device placement. J Extra Corpor Technol2016; 48(1): 39–42.
57.
UrbanowiczTOlasińska-WiśniewskaALigowskiM, et al.Bivalirudin resistance during heart transplantation surgery. Transplantation Reports2021; 6: 100072. DOI: 10.1016/j.tpr.2020.100072.
58.
McMenimanWJChardRBNorrieJ, et al.Cardiac surgery and heparin induced thrombocytopaenia (HIT): a case report and short review. Heart Lung Circ2012; 21: 295–299.
59.
FedermanMDragomerDGrantS, et al.Use of bivalirudin for anticoagulation during implantation of total artificial heart. J Extra Corpor Technol2014; 46(2): 170–172.
60.
DuggalNHaftJEngorenM, et al.Pulmonary endarterectomy under hypothermic circulatory arrest in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth2016; 30: 741–745.
L’AcquaCJulianoGNafiM, et al.Dealing with bivalirudin and core temperature during cardiac surgery. Perfusion2017; 32: 422–423.
63.
SalemiAAgrawalYPFontesMA. An assay to monitor bivalirudin levels on cardiopulmonary bypass. Ann Thorac Surg2011; 92: 332–334.
64.
GattPAnthony GaleaSBusuttilW, et al.Bivalirudin as an alternative anticoagulant for cardiopulmonary bypass during adult cardiac surgery-A change in practice. J Extra Corpor Technol2017; 49(1): 49–53.
65.
BoysanECirciRBeyazalOF, et al.Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy. J Cardiothorac Surg2023; 18: 258. DOI: 10.1186/s13019-023-02359-2.
66.
DragomerDChalfantABiniwaleR, et al.Novel techniques in the use of bivalirudin for cardiopulmonary bypass anticoagulation in a child with heparin-induced thrombocytopenia. Perfusion2011; 26: 516–518.
67.
Ricardo Argueta-MoralesIOlsenMCDecampliWM, et al.Alternative anticoagulation during cardiovascular procedures in pediatric patients with heparin-induced thrombocytopenia. J Extra Corpor Technol2011; 44(2): 69–74.
68.
WarkentinTEGreinacherA. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg2003; 76: 638–648.
69.
MorshuisMBoergermannJGummertJ, et al.A modified technique for implantation of the HeartWareTM left ventricular assist device when using bivalirudin anticoagulation in patients with acute heparin-induced thrombocytopenia. Interact Cardiovasc Thorac Surg2013; 17: 225–226.
70.
KosterABuzSKrabatschT, et al.Effect of modified ultrafiltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different filtration strategies. J Card Surg2008; 23: 655–658.
71.
WongJKTianYShuttleworthP, et al.Case report: a thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation. Anesth Analg2010; 111: 609–612.
72.
SimsirSASchwarzERCzerLSC, et al.Heart transplantation using bivalirudin as anticoagulant. Interact Cardiovasc Thorac Surg2010; 10: 150–151.
73.
LjajikjEZittermannAMorshuisM, et al.Bivalirudin anticoagulation for left ventricular assist device implantation on an extracorporeal life support system in patients with heparin-induced thrombocytopenia antibodies. Interact Cardiovasc Thorac Surg2017; 25: 898–904.
74.
KosterANiedermeyerJGummertJ, et al.Low dose bivalirudin anticoagulation for lung transplantation with extracorporeal membrane oxygenation in a patient with acute heparin-induced thrombocytopenia. Eur J Cardio Thorac Surg2017; 51: 1009–1011.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
